The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ ALL?
Featured:
Nicholas J. ShortDuring the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the ALL Hub spoke with Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Philadelphia-positive (Ph+) ALL?
Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ ALL?
Short presents promising safety and efficacy data from a single-arm phase II study investigating a combination of ponatinib + blinatumomab, in adult patients with newly diagnosed or relapsed/refractory Ph+ ALL.
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?